Epizyme, Inc. (NASDAQ:EPZM) – Wedbush lifted their FY2017 EPS estimates for Epizyme in a research report issued on Wednesday. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn ($2.11) per share for the year, up from their previous forecast of ($2.17). Wedbush currently has a “Outperform” rating and a $24.00 target price on the stock. Wedbush also issued estimates for Epizyme’s Q4 2017 earnings at ($0.55) EPS, Q1 2018 earnings at ($0.54) EPS, Q4 2018 earnings at ($0.46) EPS, FY2018 earnings at ($2.09) EPS, FY2019 earnings at ($1.83) EPS, FY2020 earnings at ($1.57) EPS and FY2021 earnings at ($0.43) EPS.

Epizyme (NASDAQ:EPZM) last posted its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.07. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 55.41%. COPYRIGHT VIOLATION NOTICE: “FY2017 EPS Estimates for Epizyme, Inc. (EPZM) Lifted by Analyst” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/06/19/fy2017-eps-estimates-for-epizyme-inc-epzm-lifted-by-analyst.html.

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Several other equities research analysts have also recently commented on the company. Leerink Swann restated an “outperform” rating and set a $31.00 price target on shares of Epizyme in a research note on Friday. Citigroup Inc. upped their price target on Epizyme from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday. Oppenheimer Holdings, Inc. set a $26.00 price target on Epizyme and gave the stock a “buy” rating in a research note on Wednesday, June 14th. Royal Bank Of Canada set a $20.00 price target on Epizyme and gave the stock a “buy” rating in a research note on Monday, June 12th. Finally, Cowen and Company restated a “buy” rating on shares of Epizyme in a research note on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $23.80.

Epizyme (EPZM) opened at 13.65 on Monday. Epizyme has a 12-month low of $7.02 and a 12-month high of $18.50. The stock’s market capitalization is $796.59 million. The stock’s 50 day moving average is $15.13 and its 200 day moving average is $13.74.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new position in Epizyme during the fourth quarter valued at about $351,000. State Street Corp boosted its position in Epizyme by 49.4% in the fourth quarter. State Street Corp now owns 1,088,635 shares of the biopharmaceutical company’s stock valued at $13,173,000 after buying an additional 359,859 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Epizyme by 17.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 40,387 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 5,919 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in Epizyme by 11.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 30,680 shares of the biopharmaceutical company’s stock valued at $371,000 after buying an additional 3,269 shares during the last quarter. Finally, Deerfield Management Co. boosted its position in Epizyme by 449.9% in the fourth quarter. Deerfield Management Co. now owns 1,601,049 shares of the biopharmaceutical company’s stock valued at $19,373,000 after buying an additional 1,309,870 shares during the last quarter. Hedge funds and other institutional investors own 81.18% of the company’s stock.

In other Epizyme news, insider Robert A. Copeland sold 5,000 shares of the stock in a transaction on Tuesday, April 4th. The stock was sold at an average price of $16.36, for a total value of $81,800.00. Following the completion of the transaction, the insider now owns 33,538 shares in the company, valued at $548,681.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew E. Singer sold 2,013 shares of the stock in a transaction on Friday, March 31st. The stock was sold at an average price of $17.09, for a total value of $34,402.17. Following the completion of the transaction, the chief financial officer now owns 36,175 shares of the company’s stock, valued at approximately $618,230.75. The disclosure for this sale can be found here. Insiders sold 29,513 shares of company stock valued at $478,677 in the last quarter. 25.40% of the stock is currently owned by company insiders.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.